Новые аспекты фармакотерапии ревматоидного артрита: ингибиторы малых молекул

1. <div><p>McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med 2012;365:2205-19.</p><p>Sweeney S.E., Firestein G.S. Primer: signal transduction in rheumatic disease — a clinician's guide. Nat Clin Pract Rheumatol 2007;3:651-60.</p><p>Senott L., Vencovsky J., Pavelka K. et al. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009;9:102-7.</p><p>Bonila-Herman M.G., Miranda-Carus M.E., Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology 2011, May 26 (Epub. ahead of print).</p><p>Kontzias A., Laurence A., Gadiba M., O’Shea J.J. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Reports 2012;4:5.</p><p>Seavey M.M., Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol 2012;83:1136-45.</p><p>Pesu M., Laurence A., Kishore N. et al. Therapeutic targeting of Janus kinase. Immunol Rev 2008;223:132-42.</p><p>Ghoreschi K., Laurence A., O’Shea J.J. Janus kinases in immune signaling. Immunol Rev 2009;228:273-87.</p><p>D’Aura Swanson C., Paniagua R.T., Lindstrom T.M., Robinson W.H. Tyrosine kinases as target for the treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009;5:317-24.</p><p>Cohen S., Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis. Curr Opin Rheumatol 2010;22:330-6.</p><p>Riese R.J., Krishnaswami S., Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010;24:513-26.</p><p>Okamoto H., Kobayashi A. Tyrosine kinased in rheumatoid arthritis. J Inflam 2011;8:21.</p><p>Cohen S. Small molecular therapies for rheumatoid arthritis: where do we stand? Expert Opin Invest Drugs 2012;21:23-31.</p><p>Alicea-Velazquez N.L., Boggon T.J. The use of structural biology in janus kinase targeted drug discovery. Curr Drug Targets 2011;12:546-55.</p><p>Changelian P.S., Flanagan M.E., Ball D.J. et al. Prevention оf organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8.</p><p>Flanagan M.E., Blumenkopf T.A., Brisette W.H. et al. Discovery of CP-690 550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ trancplantant rejection. J Med Chem 2010;53:8468-84.</p><p>Meyer D.M., Jesson M.I., Li X. et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41.</p><p>Changelian P.S., Moshinsky D., Kuhl C.F. et al. The specificity of JAK3 kinase inhibitors. Blood 2007;111:2155-7.</p><p>Milici A.J., Kudlacz E.M., Audoly L. et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthr Res Ther 2008;10:R14.</p><p>Walker J.G., Ahern M.J., Coleman M. et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006;65:149-56.</p><p>Tanaka Y., Yamaoka K. Cytokine-mediated signaling as targets for treatment of rheumatoid arthritis: a JAK kinase inhibitor in vitro and in vivo. Int J Clin Rheumatol 2011;6:439-44.</p><p>Maeshima K., Yamaoka K., Kubo S. et al. A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-γ and IL-17 production by human CD4+ T cells. Arthr Rheum 2011 (Epub. ahead of print).</p><p>Ghoreshi K., Jesson M., Li X. et al. Modulation oh innate and adaptive immunity responses by tofacitinib. J Immunol 2011;186:4234-43.</p><p>Migita K., Koga T., Komori A. et al. Influence of Janus Kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol 2011;38:2309-17.</p><p>Rosengren S., Corr M., Firestein G.S., Boyle D.L. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; April 3 (Epub. ahead of print).</p><p>Migita K., Komori A., Torigoshi T. et al. CP690,550 inhibita oncostatin M- induced JAK/STAT signaling pathway in rheumatoid arthritis. Arthr Res Ther 2011;13:R72.</p><p>Cohen S., Zwillich S.H., Chow L. et al. Co-administration of JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol 2010;69:143-51.</p><p>Kremer J.M., Bloom B.J., Breedveld F.C. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results from a randomized, double-blind, placebo-controlled Phase IIa trial of three dose levels of CP-690,550 versus placebo. Arthr Rheum 2009;60:1895-905.</p><p>Coombs J.H., Bloom B.J., Breedveld G.C. et al. Improved pain, physical function and health status in patients with rheumatoid arthritis treated with CP 690,550, an orally active Janus kinase (Jak) inhibitor: results from a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2010;69:413-6.</p><p>Kremer J.M., Cohen S., Wilkinson B.E. et al. A phase 2b doseranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthr Rheum 2011; Oct 11 (Epub. ahead of print).</p><p>Fleischman R., Cutolo M., Genovese M.C. et al. Phase Ib doseranging study of the oral KAK inhibition Tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthr Rheum 2012;64:617-29.</p><p>Tanaka Y., Suzuki M., Nakamura H. et al. Phase 2 study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and inadequate response to methotrexate. Arthr Care Res 2011 (Epub. ahead of print).</p><p>Fleishmann R., Kremer J., Cush J. et al. Phase 3 study of oral JAK inhibitor Tasocitinib (CP-690 550) monotherapy in patients with active rheumatoid arthritis. Arthr Rheum 2010;62:LB8.</p><p>Strand V., Kanik K.S., Connell C. et al. ORAL SOLO (A39921045): effects of the oral JAK inhibitor tofacitinib (CP-690,550) monotherapy on patients reported outcomes in a phase 3 study of active rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl. 3):88.</p><p>Fleishmann R., Kremer J., Connell C. et al. ORAL SOLO (A3921045): a phase 3 study of oral JAK inhibitor tofacitinib (CP-690,550) monotherapy in patients with active rheumatoid arthritis: subgroup analysis of efficacy. Ann Rheum Dis 2011;70(Suppl. 3):600.</p><p>Kremer J., Li Z., Hall S. et al. Tofacitinib (CP-690 550), an oral JAK inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann Rheum Dis 2011;70(Suppl. 3):170.</p><p>Van der Heijde D., Tanaka Y., Fleishmann R. et al. Tofacitinib (CP-690 550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study. Arthr Rheum 2011;63:S1017.</p><p>Van Vollenhoven R., Fleishmann R., Cohen S. et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, or adalimumab versus placebo in patients with rheumatoid arthritis on background methotrexate: a phase 3 study. Arthr Rheum 2011;63(Suppl. 10):S153.</p><p>Burmester G., Blanco R., Charles-Schoeman C. et al. Tofacitinib (CP-690 550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with inadequate response to tumor necrosis factor inhibitors: a 6-month phase 3 study. Arthr Rheum 2011;63(Suppl. 10):279.</p><p>Cohen S., Radominski S., Asavantanabodee P. et al. Tofacitinib (CP-690 550), an oral Janus 3 inhibitor, analysis of infections and all-causes mortality across phase 3 and long term extension studies in patients with rheumatoid arthritis. Arthr Rheum 2011;63(Suppl. 10):S153.</p><p>Wollenhaupt J., Silverfield J., Lee E.B. et al. Tofacitinib (CP-690 50), an oral Janus 3 inhibitor in the rheumatoid arthritis: open-label, long term extension studied up to 36. Arthr Rheum 2011;63:(Suppl. 10):S152.</p><p>Hoock T., Hogan J., Mahajan S. et al. VX-509, an orally available Janus Kinase 3 (JAK3) specific inhibitor, showed robust activity in pre-clinical models of abberant immune inflammatory function. Arthr Rheum 2011;63(Suppl. 10):1136</p><p>Fleishmann R., Spencer-Green G., Fan F. et al. Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Arthr Rheum 2011;63(Suppl. 10):LB3.</p><p>Belli B., Brigham D., Dao A. et al. AC430, a potent JAK2 inhibitor, provides protection in multiple inflammatory and autoimmune disease models. Presented at: ACR annual meeting; November 6—11, 2010; Atlanta, Ga. Abstr. 269.</p><p>Goh C., Hart S., Kiang Y. et al. SB1578, a novel selective JAK2 inhibitor, is highly efficacious in rodent models of rheumatoid arthritis. Arthr Rheum 2010;62(Suppl.):S299.</p><p>Stump K.L., Lu L.D., Dobrzanski P. et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthr Res Ther 2011;13:R68.</p><p>Williams W.V., Scherle P., Shi J. et al. Initial efficacy of INCB018424, a selective Janus kinase 1&amp;2 (JAK 1&amp;2) inhibitor in rheumatoid arthritis (RA). Presented at: EULAR annual congress; June 11-14, 2008; Paris, France. Abstr. OP-0044.</p><p>Greenwald M.W., Fidelus-Gort R., Levy R. et al. A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor, in subjects with active rheumatoid arthritis. Arthr Rheum 2010;62(Suppl.):S911.</p><p>Fridman J.S., Scherle P.A., Collins R. et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: pre-clinical characterisation of INCB028050. J Immunol 2010;184:5298-307.</p><p>Vanhoutte F., Galien R., Vets E. et al. GLPG0634 shows selective inhibition of JAK1 and maintained JAK-STAT suppression in healthy volunters. Arthr Rheum 2011;(Suppl. 10);2210.</p><p>Verstovsek S., Kantarjian H., Mesa R.A. et al. Safety and efficacy of INCB018424, JAK1 and JAK2 inhibitor in myelofibrosis. N Engl J Med 2010;363:1117-27.</p><p>Hammaker D., Firestein G.S.“Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis 2010;69(Suppl. 1):i77—82.</p><p>Pine P.R., Chang B., Schoettler N. et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel SyK inhibitor. Clin Immunol 2007;124:244-57.</p><p>Genovse M.C., Kavanaugh A., Weinblatt M.E. et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not responde to biologic agents. Arthr Rheum 2011;63:337-45.</p><p>Weinblatt M.E., Kavanaugh A., Burgos-Vargas R. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthr Rheum 2008;58:3309-18.</p><p>Weinblatt M.E., Kavanaugh A., Genovese M.C. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12.</p><p>Weinblatt M.E., Kavanaugh A., Genovese M.C. et al. Effects of the oral Syk inhubitor, fostamatinib, (R788), on health-related quality of life in a phase II study of active rheumatoid arthritis. Arthr Rheum 2011;63:S158.</p><p>Kavanaugh A., Weinblatt M.E., Genovese M.C. et al. Long-term safety of fostamatinib (R788) in patients with rheumatoid arthritis: analysis of clinical trial data from 2 years of exposure. Arthr Rheum 2011;63:S1018.</p><p>Baluom M., Samara E., Grossbard E.B., Lau D.T. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol 2011 (Epub. ahead of print).</p><p>Lawendy N., Krishnaswami S., Wang R. et al. Effect of CP-690,550, an oral active Janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol 2009;49:423-9.</p><p>McInnes I., Kim H.-Y., Lee S. et al. Phase 2 study of the effects of open-label tofacitinib (CO0690,550) and double-blind atorvastatin on lipid in patients with active rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl. 3):169.</p><p>Fleishmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 2012;24:335-41</p><p>Lindstrom T.M., Robinson W.H. A multitude of kinases-which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin N Am 2010;36:367-83.</p><p>Genovese M.C. Inhibition of p38: has the fat lady sung? [editorial]. Arthr Rheum 2009;60:317-20.</p><p>Damjanov N., Kauffman R.S., Spencer-Green G.T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthr Rheum 2009;60:1232-41.</p><p>Cohen S.B., Cheng T.-T., Chindalore V. et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthr Rheum 2009;60:335-44.</p><p>Alten R.E., Zerbini C., Jeka S. et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 2010;69:364-7.</p><p>Genovese M.C., Gao L., Yin J. et al. Proof of concept study for a potent p38 MAPK dual action inhibitor BMS-582949 in subjects with RA receiving concomitant methotrexate. Presented at: ACR annual meeting; November 6—11, 2010; Atlanta, Ga. Abstr. 1119.</p><p>Krausz S., Boumans M.J.H., Gerlag D.M. et al. A phase IIA, randomized, double-blind, placebo-controlled trial of Apilimod Mesylate, an IL-12/23 inhibitor, in patients with rheumatoid arthritis. Arthr Rheum 2011;Nov 07 (Epub. ahead of print).</p><p>Duvallet E., Semerano L., Assier E. et al. Interleukin 23: a key cytokine in inflammatory diseases. Ann Med 2011;63:1159-69.</p><p>Sands B.E., Jacobson E.W., Sylwestrowicz T. et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin 12/23 inhibitor apilimod mesylate for treatment of active Crohn’s disease. Inflamm Bowel Dis 2010;16:1209-18.</p><p>Mannon P.J., Fuss I.J., Mayer C.O. et al. Anti-interleukin - 12 antibody for active Crohn’s disease. N Engl J Med 2004;351:2069-79.</p><p>Fleischmann R., Poiley J., Stoilov R. et al. The oral S1P lyase inhibitor (A.K.A. LX2931) demonstrates favorable safety and potential clinical benefit at 12 weeks in phase 2 proof-of-concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy. Ann Rheum Dis 2011; 70(Suppl. 3):87.</p><p>ClinicalTrials.gov. Study of apremilast to evaluate safety and effectiveness for patients with rheumatoid arthritis. 2011. Accessed 5/31/11 at: http://clinicaltrials.gov/ct2/show/NCT01285310?term=Study+of+ Apremilast+to+Evaluate+the+Safety+and+Effectiveness+for+Pati ents+With+ Rheumatoid+Arthritis&amp;rank=1</p><p>ClinicalTrials.gov. The controlled trial of apremilast for rheumatoid arthritis treatment (CARAT). 2011. Accessed 5/31/11 at: http://clinicaltrials.gov/ct2/show/NCT01250548?term=The+ Controlled +Trial+of+Apremilast+for+Rheumatoid+Arthritis+ Treatment+%28CARAT% 29&amp;rank=1</p><p>ClinicalTrials.gov. Concomitant use of apremilast for the treatment of active RA despite TNF-Inhibition and methotrexate-CATARA. 2010. Accessed 6/1/11 at: http://clinicaltrials.gov/ct2/show/NCT01204138? term=Rheumatoid+arthritis&amp;cntry1=NA%3AUS &amp;age=12&amp;phase=12&amp;rcv_s=01%2F01%2F2005 &amp;rcv_e=12%2F31%2F2011&amp;rank=210</p><p>ClinicalTrials.gov. Oral CF-101 tablets treatment in patients with rheumatoid arthritis. Accessed 7/18/11: http://clinicaltrials.gov/ct2/show/NCT01034306?term=Oral+CF 101&amp;rank=1</p><p>ClinicalTrials.gov. A study of PF-04171327 in the treatment of the signs and symptoms of rheumatoid arthritis. 2010. Accessed 5/31/11: http://clinicaltrials.gov/ct2/show/NCT00938587?term=PF- 04171327&amp;rank=2</p><p>Kay J., Morales R., Bellatin L. et al. Treatment of rheumatoid arthritis (RA) with a MEK kinase inhibitor: results of a 12-week, randomized, placebo-controlled phase 2 study in patients with active RA on a background of methotrexate. Presented at: EULAR annual congress; June 16—19, 2010; Rome, Italy, Abstr. OP0013.</p><p>Stock T., Bloom B.J., Wang X. et al. Phase 2 evaluation of CE-224,535, a selective antagonist of the P2X7 receptor, for the treatment of rheumatoid arthritis in patients with an inadequate response to methotrexate. Presented at: EULAR annual congress; June 16-19, 2010; Rome, Italy, Abstr. THU0217.</p><p>Roman-Blas J.A., Castaneda S., Cutolo M., Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor p agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthr Care Res (Hoboken) 2010;62:1588-93.</p><p>Littman B.H. Translation strategies to implement personalized medicine: rheumatoid arthritis examples. Personal Med 2009;6:429-37.</p><p>Kuriya B., Arkema E.V., Bykerk V.P., Keystone E.C. Efficacy of initial methotrexate monotherapy versus combination therapy with biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010;69(7):1298-304.</p><p>Gaujoux-Viala C., Smolen J.S., Landewe R. et al. Current evidence for management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systemic literature review informing EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.</p></div><br />